marine drugs Marine Compounds and Cancer 2017 Edited by Friedemann Honecker and Sergey A. Dyshlovoy Printed Edition of the Special Issue Published in Marine Drugs www.mdpi.com/journal/marinedrugs Marine Compounds and Cancer Special Issue Editors Friedemann Honecker Sergey A. Dyshlovoy MDPI Basel Beijing Wuhan Barcelona Belgrade Special Issue Editors Friedemann Honecker Tumor and Breast Center ZeTuP St. Gallen Switzerland Sergey A. Dyshlovoy University Medical Center Hamburg-Eppendorf Germany Editorial Office MDPI AG St. Alban-Anlage 66 Basel, Switzerland This edition is a reprint of the Special Issue published online in the open access journal Marine Drugs (ISSN 1660-3397) in 2017 (available at: http://www.mdpi.com/journal/marinedrugs/special_issues/marine-compounds- cancer). For citation purposes, cite each article independently as indicated on the article page online and as indicated below: Lastname, F.M.; Lastname, F.M. Article title. Journal Name Year, Article number, page range. First Edition 2018 ISBN 978-3-03842-765-0 (Pbk) ISBN 978-3-03842-766-7 (PDF) Articles in this volume are Open Access and distributed under the Creative Commons Attribution license (CC BY), which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book taken as a whole is © 2018 MDPI, Basel, Switzerland, distributed under the terms and conditions of the Creative Commons license CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/). Table of Contents About the Special Issue Editors ..................................... v Sergey A. Dyshlovoy and Friedemann Honecker Marine Compounds and Cancer: 2017 Updates doi: 10.3390/md16020041 ....................................... 1 Beatriz Mart ´ınez-Poveda,Ana R. Quesada and Miguel Angel´ Medina Pleiotropic Role of Puupehenones in Biomedical Research doi: 10.3390/md15100325 ....................................... 4 Aida Sarmiento-Vizca´ıno, Alfredo F. Bra ˜na, Ignacio P´erez-Victoria, Jesus ´ Mart´ın, Nuria de Pedro, Mercedes de la Cruz, Caridad D´ıaz, Francisca Vicente, Jos´eL. Acua, Fernando Reyes, Luis A. Garca and Gloria Blanco Paulomycin G, a New Natural Product with Cytotoxic Activity against Tumor Cell Lines Produced by Deep-Sea Sediment Derived Micromonospora matsumotoense M-412 from the Aviles´ Canyon in the Cantabrian Sea doi: 10.3390/md15090271 ....................................... 17 Julia Sperlich, Russell Kerr and Nicole Teusch The Marine Natural Product Pseudopterosin Blocks Cytokine Release of Triple-Negative Breast Cancer and Monocytic Leukemia Cells by Inhibiting NF-κB Signaling doi: 10.3390/md15090262 ....................................... 26 Xian Sun, Yu Zhong, Hongtian Luo and Yufeng Yang Selenium-Containing Polysaccharide-Protein Complex in Se-Enriched Ulva fasciata Induces Mitochondria-Mediated Apoptosis in A549 Human Lung Cancer Cells doi: 10.3390/md15070215 ....................................... 42 Lan-Ting Xin, Lu Liu, Chang-Lun Shao, Ri-Lei Yu, Fang-Ling Chen, Shi-Jun Yue, Mei Wang, Zhong-Long Guo, Ya-Chu Fan, Hua-Shi Guan and Chang-Yun Wang Discovery of DNA Topoisomerase I Inhibitors with Low-Cytotoxicity Based on Virtual Screening from Natural Products doi: 10.3390/md15070217 ....................................... 53 Michaela Dithmer, Anna-Maria Kirsch, Elisabeth Richert, Sabine Fuchs, Fanlu Wang, Harald Schmidt, Sarah E. Coupland, Johann Roider and Alexa Klettner Fucoidan Does Not Exert Anti-Tumorigenic Effects on Uveal Melanoma Cell Lines doi: 10.3390/md15070193 ....................................... 62 Mohamed-Elamir F. Hegazy, Abdelsamed I. Elshamy, Tarik A. Mohamed, Ahmed R. Hamed, Mahmoud A. A. Ibrahim, Shinji Ohta and Paul W. Par´e Cembrene Diterpenoids with Ether Linkages from Sarcophyton ehrenbergi: An Anti- Proliferation and Molecular-Docking Assessment doi: 10.3390/md15060192 ....................................... 76 Tanja Schirmeister, Swarna Oli, Hongmei Wu, Gerardo Della Sala, Valeria Costantino, Ean-Jeong Seo and Thomas Efferth Cytotoxicity of Endoperoxides from the Caribbean Sponge Plakortis halichondrioides towards Sensitive and Multidrug-Resistant Leukemia Cells: Acids vs. Esters Activity Evaluation doi: 10.3390/md15030063 ....................................... 90 iii Xinya Xu, Xiaoyong Zhang, Xuhua Nong, Jie Wang and Shuhua Qi Brevianamides and Mycophenolic Acid Derivatives from the Deep-Sea-Derived Fungus Penicillium brevicompactum DFFSCS025 doi: 10.3390/md15020043 .......................................101 iv About the Special Issue Editors Friedemann Honecker, MD, PhD, studied medicine in Germany and the UK between 1991 and 1999. In 1999, he started his medical and scientific career in internal medicine with a focus on Oncology and Hematology at the University Medical Center Tübingen, Germany. From 2002 to 2004, he did his PhD in experimental pathology at Rotterdam Erasmus MC in Rotterdam, NL, focusing on germ cell tumor development and mechanisms of drug resistance. From 2005 to 2013, he worked in the Department of Oncology and Hematology at Hamburg University Hospital, both as a senior consultant in Oncology and group leader of the "Laboratory of Experimental Oncology" of the University Cancer Center Hamburg (UCCH), a comprehensive cancer center. Since 2013, he has worked as an oncologist and researcher at the Tumor and Breast Center ZeTuP in St. Gallen, Switzerland. His main research interests are breast cancer and genitourinary cancers, development of new anti-cancer substances, and the treatment of elderly cancer patients. He has published over 90 original Pub-Med listed articles and reviews, and is author of numerous book chapters. Sergey A. Dyshlovoy, PhD, trained in chemistry and biochemistry in the Russian Federation and in Germany. He started his scientific career in 2006. Between 2009 and 2012, he did his PhD in chemistry, focusing on the elucidation of structure, and mode of action of novel small-molecule marine bioactive compounds, showing anticancer activity in the in G.B. Elyakov Pacific Institute of Bioorganic Chemistry (Vladivostok, Russian Federation). Since 2012, he has been a senior researcher at both this institute and at the Far Eastern Federal University (Vladivostok). Since 2013, he has worked as a post-doctoral researcher at the University Medical Center Hamburg-Eppendorf (Hamburg, Germany) in the Department of Oncology. Since 2014, he has been a member of the Commission of Experts of the Russian Scientific Foundation. His main research interest is the investigation of mechanisms of anticancer action of novel marine compounds with a strong focus on autophagy. To date, he has published over 50 research articles. v marine drugs Editorial Marine Compounds and Cancer: 2017 Updates Sergey A. Dyshlovoy 1,2,3,*and Friedemann Honecker 2,4,* 1 Laboratory of Marine Natural Products Chemistry, G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far-East Branch, Russian Academy of Sciences, 690022 Vladivostok, Russia 2 Laboratory of Experimental Oncology, Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald-Tumorzentrum, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany 3 School of Natural Sciences, Far East Federal University, 690022 Vladivostok, Russia 4 Tumor and Breast Center ZeTuP St. Gallen, CH-9006 St. Gallen, Switzerland * Correspondence: [email protected] (S.A.D.); [email protected] (F.H.) Received: 15 January 2018; Accepted: 22 January 2018; Published: 24 January 2018 By the end of 2017, there were seven marine-derived pharmaceutical substances that have been approved by the FDA for clinical use as drugs. Four of them are approved for the treatment of cancer, namely cytarabine (Cytosar-U®, first approved in 1969 for the treatment of leukemia), eribulin mesylate (Halaven®, first approved in 2010 for the treatment of metastatic breast cancer), brentuximab vedotin (Adcetris®, first approved in 2011 for the treatment of anaplastic large T-cell malignant lymphoma, and Hodgkin’s lymphoma), and trabectidine (Yondelis®, first approved in 2015 for the treatment of soft tissue sarcoma and ovarian cancer) [1]. Additionally, a number of marine-derived substances with potent anticancer properties are currently undergoing different stages of clinical development in oncology and hematology. Among them are plinabulin, plitidepsin, glembatumumab vedotin, and lurbinectedin (all in Phase III clinical trials); depatuxizumab mafodotin, AGS-16C3F, polatuzumab vedotin, PM184, tisotumab vedotin, and enfortumab vedotin (all in Phase II clinical trials); GSK2857916, ABBV-085, ABBV-399, ABBV-221, ASG-67E, ASG-15ME, bryostatin, marizomib, and SGN-LIV1A (all in Phase I clinical trials) [1]. Additionally, there are around 1500 natural molecules that were isolated from marine organisms, for which potent in vivo biological activity has been described, and more than 10,000 different compounds that have exhibited in vitro activity [2]. Therefore, natural compounds are a rich reservoir of molecules showing promising bioactivity, which will most certainly lead to the further development of potent anticancer compounds in the future. To document this dynamic field of research, the topical collection “Marine Compounds and Cancer” (http://www.mdpi.com/journal/marinedrugs/special_issues/marine-compounds-cancer) of the open access journal Marine Drugs (ISSN 1660-3397) was started in 2017,